Blog
RSS FeedPosted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
Posted by Michael Wonder on 02 Jul 2024
ICER publishes evidence report on treatment for anaemia in myelodysplastic syndrome
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
Posted by Michael Wonder on 30 May 2024
ICER publishes evidence report on treatment for chronic obstructive pulmonary disease
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...
Posted by Michael Wonder on 26 Mar 2024
ICER releases draft evidence report on treatment for post-traumatic stress disorder
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 05 Dec 2023
ICER releases draft evidence report on treatment for paroxysmal nocturnal haemoglobinuria
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Nov 2023
ICER releases draft evidence report on treatment for schizophrenia
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 14 Nov 2023
ICER publishes evidence report on treatment for pulmonary arterial hypertension
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
Posted by Michael Wonder on 30 Oct 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
Posted by Michael Wonder on 25 Sep 2023
ICER releases draft evidence report on treatment for pulmonary arterial hypertension
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
Posted by Michael Wonder on 14 Sep 2023
ICER publishes evidence report on gene therapy for metachromatic leukodystrophy
14 September 2023 - Using weighted analyses across all patient subpopulations, atidarsagene autotemcel would achieve common thresholds for cost effectiveness if priced ...
Posted by Michael Wonder on 26 Jul 2023
ICER releases draft evidence report on treatment for metachromatic leukodystrophy
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
Posted by Michael Wonder on 18 Apr 2023
Cost effectiveness thresholds used by study authors (1990-2021)
18 April 2023 - For decades, many US authors of cost effectiveness analyses referenced a common benchmark or threshold—$50 000 per quality-adjusted ...